InvestorsHub Logo
Followers 2
Posts 2974
Boards Moderated 0
Alias Born 06/23/2017

Re: None

Wednesday, 02/21/2018 2:41:18 PM

Wednesday, February 21, 2018 2:41:18 PM

Post# of 44784
We are approaching 13 months since enrolment began in HCT trial. They hired a secretive "leading" CRO remember. Maybe it was so they can keep their definition of "leading" a secret. They think Pluristem are "leaders" after all. And resumes are chalked full of terms like "successful companies" without giving the actual names of them. Keeps em guessing. So it MUST be incredible.

Four sites trying to recruit 30 patients. Less than 8 per site. If they get one per month per site, we will be done by.... Um...last year. But I guess this is not a serious condition like CLI so enrolment would be slow.

But CLI boy, we're going to get approved this year for sure!!! They only need 123 enrolled. 14 sites probably easily enrolling patients. Piece of cake. Probably just going to halt the trial outright, and approve immediately. Did anyone in the two trials of 27 patients not make it to 1 year AFS? And statistical trials aren't really necessary. More of a way to just keep FDA workers employed. If it works on one, good for all.

I can't believe this phase 3 company is sitting in the $1.30's. Must be the controller. It's the only explanation. Remember everyone should load up... anything under $2 is a steal. Besides, once that deal is signed, the controller will go away. Whew!!!